Nasdaq: RARE

Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker RARE. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
RARE
Exchange
Nasdaq
SEC CIK
1515673
Official filings
SEC EDGAR

Research RARE

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Ultragenyx Pharmaceutical Inc.'s stock ticker?

Ultragenyx Pharmaceutical Inc. trades under the ticker symbol RARE on Nasdaq. Its SEC Central Index Key (CIK) is 1515673.

Where can I read Ultragenyx Pharmaceutical Inc.'s SEC filings?

The RARE SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Ultragenyx Pharmaceutical Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze RARE's financial statements?

The RARE Financials page shows Ultragenyx Pharmaceutical Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does RARE compare with its peers and the market?

The RARE Peer Comparison page lines Ultragenyx Pharmaceutical Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.